Search Result

Results for "

CD8 T-cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Apoptosis (2) Aryl Hydrocarbon Receptor (1) Biochemical Assay Reagents (1) c-Fms (1) CD20 (1) CD73 (1) EBV (1) Ferroptosis (1) Galectin (1) HDAC (1) IFNAR (2) Itk (1) LAG-3 (1) MAP4K (2) MAPKAPK2 (MK2) (1) NF-κB (1) P-glycoprotein (1) PD-1/PD-L1 (6) ROCK (1) TNF Receptor (3) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (29) Infection (5) Inflammation/Immunology (13) Metabolic Disease (1)
Click Chemistry:	Azide (1)
Oligonucleotides:	CpG ODNs (2)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Click Chemistry

Oligonucleotides

Targets Recommended: Nuclear Factor of activated T Cells (NFAT)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-144088

ZYF0033 HPK1-IN-22	MAP4K	Inflammation/Immunology Cancer
ZYF0033 is effective in inhibiting hematopoietic progenitor cells HPK1, basically inhibiting MBP protein oxidation IC₅₀ 10 nM . ZYF0033 promotes anti-cancer immune response, lowers SLP76 (acid 376) oxidation. ZYF0033 Suppression 4T-1 Small mouse model with the same underlying cause, medium bulge growth length expansion DC, NK 细细和 CD107a ^{+ CD8 ⁺ T Cells, PD-1 ⁺CD8 ⁺ T Cells, TIM-3 ⁺CD8 ⁺ T Cells LAG3< sup>+}CD8 ⁺ T Cellular immersion decreases.

HY-150725C

ODN 1585 sodium	TNF Receptor IFNAR	Cancer
ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 sodium can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant .

HY-P99933

Eftilagimod alfa IMP321; LAG-3Ig	LAG-3	Cancer
Eftilagimod alfa (IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II. Eftilagimod alfa mediates antigen-presenting cell (APC) activation followed by CD8 T-cell activation. Eftilagimod alfa can be used for metastatic melanoma and metastatic breast carcinoma research .

HY-156850

ITF 3756	HDAC	Cancer
ITF 3756 is a potent and selective HDAC6 inhibitor. ITF 3756 reduces in vitro the expression of PD-L1 on human monocytes and on CD8 T cells, and shows anti-tumor activity .

HY-150725

ODN 1585	IFNAR TNF Receptor	Infection Inflammation/Immunology Cancer
ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant .

HY-159730

ERG245	Others	Cancer
ERG245 is a BCAT1 inhibitor that enhances oxidative phosphorylation (OXPHOS) in CD8 ⁺ T cells by specifically inhibiting BCAT1 activity, thereby increasing the cytotoxicity of CD8 ⁺ T cells. ERG245, in combination with Pembrolizumab (anti-PD-1, HY-P9902A), promotes tumor regression. ERG245 can be used in research related to immuno-oncology .

HY-168528

WS-917	P-glycoprotein	Cancer
WS-917 is a potent and orally active ABCB1 modulator. WS-917 enhances ABCB1 ATPase activity. WS-917 significantly enhances the antitumor effect of paclitaxel combined with anti-PD-1 antibody. WS-917 promotes CD8 ⁺ T-cell activation .

HY-P10663

EBV EBNA3A (379-387)	EBV	Infection Inflammation/Immunology
EBV EBNA3A (379-387) is an antigenic epitope that may elicit the latent-specific CD8 ⁺ T cell response in HLA-B*07:02 ⁺ individuals .

HY-156996

AGI-134	Others	Inflammation/Immunology Cancer
AGI-134 is a fully synthetic alpha-Gal glycolipid. AGI-134 invokes CD8+ T cell-mediated immunity. AGI-134 induces tumor cell destruction and phagocytosis .

HY-161564

T4/OVA	Biochemical Assay Reagents	Inflammation/Immunology
T4/OVA is a conjugate of T4 peptide (thyroxine T4) and ovalbumin. T4/OVA is a altered peptide, which can be used to stimulate OT-I CD8+ T cells .

HY-160696

ORIC-533	CD73	Cancer
ORIC-533 is an orally active, selective CD73 inhibitor with AMP-competition. ORIC-533 restores immunosuppressed CD8+ T cell proliferation and activation, triggers significant lysis and cell death of multiple myeloma cells in the bone marrow microenvironment .

HY-114440

Belapectin GR-MD-02	Galectin Apoptosis	Cancer
Belapectin (GR-MD-02) is a Galectin-3 (Gal-3) inhibitor. Belapectin drives tumor-induced immunosuppression by inducing T cell Apoptosis. Belapectin promotes tumor regression and improves survival of tumor-bearing mice through a CD8+ T cell-dependent mechanism. Belapectin binds to Gal-3 with affinity K_i of 2.8 μM .

HY-168078

PD-1/PD-L1-IN-50	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-50 (Compound LG-12) is a PD-1/PD-L1 inhibitor. PD-1/PD-L1-IN-50 increases the secretion of IFN-γ to promote CD8 + T cell activation, and activates the antitumor immunity of T cells .

HY-162415

CSF1R-IN-22	c-Fms Apoptosis	Cancer
CSF1R-IN-22 (Compound C19) is an orally effective CSF-1R selective inhibitor (IC₅₀<6 nM). CSF1R-IN-22 enhances the secretion of CXCL9 from M2 macrophages, increases CD8 ⁺ T cell infiltration. CSF1R-IN-22 boosts anti-tumor immune responses of anti-PD-1, and induces apoptosis in tumor cells. CSF1R-IN-22 can effectively reprogram M2-like TAMs (tumor-associated macrophages) to the M1 phenotype and reshape the TME by inducing the recruitment of CD8 ⁺ T cells into tumors and reducing the infiltration of immunosuppressive Tregs and MDSCs .

HY-146740

PD-1/PD-L1-IN-27	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-27 is a potent PD-1/PD-L1 inhibitor with an IC₅₀ value of 134 nM. PD-1/PD-L1-IN-27 shows antitumor effects with low T cell cytotoxicity. PD-1/PD-L1-IN-27 has the ability to activate CD8 ⁺ T cells and reduces T cell exhaustion .

HY-162065

N6F11	Ferroptosis	Cancer
N6F11 is a selective ferroptosis inducer, and can selectively induce ferroptosis by targeting TRIM25-mediated GPX4 degradation in cancer cells while sparing immune cells. N6F11 initiates HMGB1-dependent antitumor immunity mediated by CD8 ⁺ T cells .

HY-159123

KHK-6	MAP4K	Cancer
KHK-6 is an inhibitor for serine/threonine kinase hematopoietic progenitor kinase 1 (HPK 1) with an IC₅₀ of 20 nM. KHK-6 enhances CD3/CD28-induced cytokine production, enhances CD69, CD25 and HLA-DR markers on CD4+ and CD8+ T cells, and enhances T cell-mediated killing activity of SKOV3 and A549 cells .

HY-148808

Zelasudil RXC007	ROCK	Cancer
Zelasudil (RXC007) is an orally active, highly selective small molecule Rho-associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor with anti-fibrotic efficacy. Zelasudil elicits positive immunomodulatory effects in metastatic pancreatic tumors with increase of CD8+ and CD4+ T cell infiltrate into the tumor cortex and reduction in immunosuppressive FOXP3+ regulatory T cells at the tumor border. Zelasudil is promising for research of pancreatic ductal adenocarcinoma .

HY-145239

PD-1/PD-L1-IN-13	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-13 (Compound 43) is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC₅₀ value of 10.2 nM. PD-1/PD-L1-IN-13 promots CD8 ⁺ T cell activation and delays the tumor growth in the Hepa1-6 syngeneic mouse model .

HY-157055

PD-1-IN-25	PD-1/PD-L1	Cancer
PD-1-IN-25 (compound 43) is a potent PD-1/PD-L1 interaction inhibitor with an IC50 value of 10.2 nM in the HTRF assay. PD-1-IN-25 can promote CD8+ T cell activation through inhibiting PD-1/PD-L1 cellular signaling. PD-1-IN-25 delays the tumor growth .

HY-N12537

PD-1/PD-L1-IN-38	PD-1/PD-L1	Cancer
PD-1/ PD-L1-in-38 is a PD-1/PD-L1 inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8 ⁺ T cells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity .

HY-13644

Gusperimus 15-Deoxyspergualin	Others	Others
Gusperimus is a fully synthetic racemate that has a novel mechanism of action by binding to the intracellular heat shock protein hsp70 and interfering with intracellular signal transduction. This mechanism of action can enhance the effect of immunosuppressive therapy. Gusperimus can inhibit the differentiation of T cells into cytotoxic T cells, reduce the expression of IL-2 receptors on CD4 and CD8 cells, and inhibit IFN-γ-induced B cell maturation. In addition, when used with cyclosporine, tacrolimus or mycophenolate mofetil, Gusperimus can enhance the immunosuppressive effect and prevent allogeneic transplant rejection.

HY-161982

JNU-0921	TNF Receptor	Cancer
JNU-0921 is a potent and orally active CD137 inhibitor. JNU-0921 increases the mRNA expression of IFN-γ and GZMB. JNU-0921 induces luciferase activity with an EC₅₀ value of 64.07 nM.JNU-0921 enhances effector and memory function of cytotoxic CD8 ⁺ T cells (CTLs) and alleviates their exhaustion. JNU-0921 also skews polarization of helper T cells toward T helper 1 type and enhances their activity to boost CTL function. JNU-0921 shows anticancer activity .

HY-N12537A

(2R,3S)-PD-1/PD-L1-IN-38	Aryl Hydrocarbon Receptor PD-1/PD-L1	Cancer
(2R,3S)-PD-1/PD-L1-IN-38 (Compound (±)-13e) is an orally active Ah receptor (AhR) antagonist with in vivo and in vitro anticancer activity. (2R,3S)-PD-1/PD-L1-IN-38 promotes the secretion of INF-γ by CD8 ⁺T cells and inhibits the signal transduction of PD-1/PD-L1 .

HY-150298

Soquelitinib CPI-818	Itk	Inflammation/Immunology Cancer
Soquelitinib (CPI-818) is an orally active and highly selective covalent interleukin-2-inducible kinase (ITK) inhibitor. Soquelitinib is active in six different models of T cell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease with Th2 cytokine product inhibition. Soquelitinib increases tumor infiltration of normal CD8 ⁺ cells that possess enhanced T effector function .

HY-157793

SMU-L11	Toll-like Receptor (TLR) NF-κB MAPKAPK2 (MK2)	Inflammation/Immunology Cancer
SMU-L11 is a specific TLR7 agonist (EC₅₀=0.024 μM), which recruits MyD88 adapter protein and activates downstream NF-κB and MAPK signaling pathways. In murine models, SMU-L11 significantly enhances immune cell activation and promotes the proliferation of CD4 ⁺ T and CD8 ⁺ T cells, thereby directly killing tumor cells and inhibiting tumor growth. SMU-L11 can be used for cancer research, and also has the potential for studying immune system diseases .

HY-P99483

Blontuvetmab AT 004; VT 007	CD20 Adenosine Receptor	Cancer
Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak NOP affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8 T cell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma .

Cat. No.	Product Name	Type

HY-161564

T4/OVA	Biochemical Assay Reagents
T4/OVA is a conjugate of T4 peptide (thyroxine T4) and ovalbumin. T4/OVA is a altered peptide, which can be used to stimulate OT-I CD8+ T cells .

Cat. No.	Product Name	Target	Research Area

HY-P2511

Insulin β Chain Peptide (15-23)	Peptides	Metabolic Disease
Insulin β Chain Peptide (15-23) is one of the earliest antigenic epitopes to which CD8 T-cells respond .

HY-P10581A

SIIVFEKL TFA	Peptides	Inflammation/Immunology
SIIVFEKL TFA is a variant of the major MHC class I-restricted epitope SIINFEKL. SIIVFEKL TFA is an antigenic peptide, that can stimulate specific T cells in experimental settings to study the competitive interaction between T cells. SIIVFEKL TFA exhibits low affinity for the OT-I T cell receptor (TCR), and can be used for detection of CD8+ T cells .

HY-P10582A

SIYNFEKL TFA	Peptides	Inflammation/Immunology
SIYNFEKL TFA is a variant of major MHC class I-restricted epitope SIINFEKL. SIYNFEKL TFA is an antigenic peptide, that can stimulate specific T cells in experimental settings to study the competitive interaction between T cell. SIYNFEKL TFA exhibits low affinity for the OT-I T cell receptor (TCR), and can be used for detection of CD8+ T cells .

HY-P5496

AAV2 Epitope	Peptides	Others
AAV2 Epitope is a biological active peptide. (This peptide is the capsid derived immunodominant adeno-associated virus 2 (AAV2), CD8 T cell epitope. Liver toxicity observed in a clinical trial of AAV2 delivered systemically to patients with hemophilia was ascribed to killing of vector-transduced hepatocytes by capsid-specific T-cells.)

HY-P4628

TPNQRQNVC LRH-1 peptide	Peptides	Inflammation/Immunology
TPNQRQNVC is a nonapeptide and is the epitope of HLA-B0702. TPNQRQNVC induces a CD8+ T cell immune response .

HY-P5442

MOG (44-54), mouse, human, rat	Peptides	Others
MOG (44-54), mouse, human, rat is a biological active peptide. (minimal binding epitope for the CD8 + MOG‐specific T cell)

HY-P10535

AAV-8 NSL epitope	Peptides	Others
The AAV-8 NSL epitope is a specific CD8+ T cell epitope identified from the capsid of an adeno-associated virus (AAV) serotype 8. The AAV-8 NSL epitope has a high affinity for MHC I molecules and is able to bind to MHC I molecules, thereby activating CD8+ T cells. The AAV-8 NSL epitope can be used to study the impact of T cell-mediated immune responses on AAV-mediated gene transfer .

HY-P10663

EBV EBNA3A (379-387)	EBV	Infection Inflammation/Immunology
EBV EBNA3A (379-387) is an antigenic epitope that may elicit the latent-specific CD8 ⁺ T cell response in HLA-B*07:02 ⁺ individuals .

HY-P5745

TYVPANASL	Peptides	Cancer
TYVPANASL is a MHC I-binding CD8 T cell epitope of nine amino acids from HER2/neu. TYVPANASL can be used to prepare J-LEAPS vaccine .

HY-P5745A

TYVPANASL TFA	Peptides	Cancer
TYVPANASL TFA is a MHC I-binding CD8 T cell epitope of nine amino acids from HER2/neu. TYVPANASL TFA can be used to prepare J-LEAPS vaccine .

HY-P5453

CFP10 (71–85)	Peptides	Others
CFP10 (71–85) is a biological active peptide. (CFP1071–85, that elicited IFN-γ production and CTL activity by both CD4+ and CD8+ T cells from persons expressing multiple MHC class II and class I molecules)

HY-P10662

*HLA-B0801-binding EBV peptide**	Peptides	Infection Inflammation/Immunology
HLA-B0801-binding EBV peptide is an Epstein-Barr virus (EBV) epitope FLRGRAYGL. HLA-B0801-binding EBV peptide can bind to the HLA-B0801 molecule. HLA-B0801-binding EBV peptide can be presented to CD8+ T cells through HLA-B*0801 to activate a specific immune response .

HY-P10497

EBV BZLF1 (190-197)	Peptides	Others
EBV BZLF1 (190-197) is an immunodominant CEF-controlling peptide derived from Epstein-Barr virus (EBV). EBV BZLF1 (190-197) is a suitable epitope for CD8+ T cells to stimulate the release of IFNg. CTL responses to EBV BZLF1 (190-197) are diverse and cross-recognize similar peptides from both host self-proteins and bacterial proteins. EBV BZLF1 (190-197) can be used to study autoimmune diseases .

HY-P10509

IE1 peptide	Peptides	Infection
IE1 peptide refers to an antigenic peptide encoded by the immediate early (IE) gene of mouse cytomegalovirus (mCMV). IE1 peptide is one of the key antigenic peptides expressed during mCMV infection, plays a role in transcriptional activation in the life cycle of mCMV, and is one of the earliest genes expressed in the viral replication cycle. IE1 peptide is an important target for CD8+ T cell response and can be used to study the host immune response to mCMV infection .

HY-P10493

NY-ESO-1 (157–165) peptide	Peptides	Others Cancer
NY-ESO-1 (157–165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157–165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157–165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy. NY-ESO-1 (157–165) peptide can be used in the study of cancer immunotherapy .

HY-P5502

Influenza NP (311-325)	Peptides	Others
Influenza NP (311-325) is a biological active peptide. (This peptide is amino acids 311 to 325 fragment of the influenza virus nucleoprotein (NP). This bona fide MHC class II restricted epitope from influenza virus was used to study the host immunoresponse during the infection. This peptide elicits the strongest gamma interferon (IFN-gamma) production in the intracellular cytokine assays. It does not stimulate CD8 T-cells in mice.Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)

HY-P3070

H2-D b restricted epitopes VSV Nucleoprotein (52-59)	Peptides	Infection Others
H2-D b restricted epitopes VSV Nucleoprotein (52-59) is a 9-mer peptide derived from the nucleoprotein of Vesicular Stomatitis Virus (VSV). H2-D b restricted epitopes VSV Nucleoprotein (52-59) binds to MHC class I molecules and presents itself to CD8+ T cells, thereby activating cytotoxic T lymphocytes (CTLs), which can recognize and kill cells expressing the corresponding antigen. H2-D b restricted epitopes VSV Nucleoprotein (52-59) can be used in the development of CTL vaccines against Ebola virus .

Cat. No.	Product Name

HY-K0309

*Mouse CD8⁺ T Cells* Negative Selection Kit**
MCE Mouse CD8⁺ T Cells Negative Selection Kit is designed for the isolation of CD8⁺ T cells from single cell suspensions of mouse spleen cells and lymph nodes.

Cat. No.	Product Name	Target	Research Area

HY-P99933

Eftilagimod alfa IMP321; LAG-3Ig	LAG-3	Cancer
Eftilagimod alfa (IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II. Eftilagimod alfa mediates antigen-presenting cell (APC) activation followed by CD8 T-cell activation. Eftilagimod alfa can be used for metastatic melanoma and metastatic breast carcinoma research .

HY-P99159

Ivuxolimab	Inhibitory Antibodies	Cancer
Ivuxolimab is an OX40 (also known as CD134; TNFRSF4) agonist monoclonal antibody. OX40 is a costimulatory receptor expressed on activated CD4 ⁺ and CD8 ⁺ T cells. Ivuxolimab shows antitumor activity, with potential immunostimulatory activity .

HY-P99431

KY-1044 Alomfilimab; SAR 445256	Inhibitory Antibodies	Inflammation/Immunology Cancer
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS ^high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8 ⁺ T_Eff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .

HY-P99483

Blontuvetmab AT 004; VT 007	CD20 Adenosine Receptor	Cancer
Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak NOP affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8 T cell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma .

Cat. No.	Product Name		Classification

HY-159123

KHK-6		Azide
KHK-6 is an inhibitor for serine/threonine kinase hematopoietic progenitor kinase 1 (HPK 1) with an IC₅₀ of 20 nM. KHK-6 enhances CD3/CD28-induced cytokine production, enhances CD69, CD25 and HLA-DR markers on CD4+ and CD8+ T cells, and enhances T cell-mediated killing activity of SKOV3 and A549 cells .

Cat. No.	Product Name		Classification

HY-150725C

ODN 1585 sodium		CpG ODNs
ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 sodium can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant .

HY-150725

ODN 1585		CpG ODNs
ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CD8 T-cells

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

NaturalProducts

Click Chemistry

Oligonucleotides

Natural
Products